Sinopharm's two vaccines have over 70% efficacy in Phase III trials
Updated 15:27, 30-May-2021

Chinese vaccine manufacturer Sinopharm claims two of its COVID-19 vaccines have over 70 percent efficacy based on Phase Three clinical trials on inactivated vaccines. According to the first detailed results of a large late-stage study published in the Journal of the American Medical Association on Wednesday, the two inactivated vaccines demonstrated efficacies of 72.8 percent and 78.1 percent. 

Search Trends